Fig. 5: DILA1 promotes tamoxifen resistance in vivo.
From: LncRNA DILA1 inhibits Cyclin D1 degradation and contributes to tamoxifen resistance in breast cancer
MCF7-Re cells were inoculated into the mammary fat pads of NOD/SCID mice. When tumors became palpable, MCF7-Re tumors were injected with NC or DILA1-ASOs intratumorally. The tumor picture (a) and the tumor growth curves (b) are shown and compared among the groups. c Immunohistochemistry (IHC) staining of Ki67, Cyclin D1, p-D1(Thr286), and p-Rb(Ser780) and in situ hybridization (ISH) staining of DILA1 in the tumors. Representative images of six xenografts from each group are shown. d–h The quantification of IHC scores of Ki67(d), Cyclin D1(e), p-D1(Thr286) (f), and p-Rb(Ser780) (g) and ISH scores of DILA1 (h). For b, d–h, n = 6 mice per group, means ± s.d. are shown, and p values were determined by two-tailed Student’s test. Scale bars represents 50 µm.
